Intrathecal administration of iopamidol in children: clinical and diagnostic results.
An open label, noncomparative clinical trial of intrathecal iopamidol in children was performed. Sixty-one subjects between the ages of 24 days and 17 years were studied. Opacification of the subarachnoid space was adequate in all cases. Mild adverse reactions were detected in 10% of the participants. Seizures, EEG alterations or other severe reactions did not occur. The findings confirm the efficacy and safety of iopamidol as an intrathecal contrast medium in pediatrics.
Wells
R G
RG
Department of Radiology, Children's Hospital of Wisconsin, Milwaukee.
Seidel
F G
FG
Sty
J R
JR
Swick
H M
HM
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007278:Injections, Spinal; D007479:Iopamidol / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D009192:Myelography
D007479:Iopamidol